|Day Low/High||62.01 / 64.49|
|52 Wk Low/High||27.20 / 68.90|
Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.
What drives the trading action are structural issues, not macroeconomic news events or political drama.
Duchenne Organizations Led by Parent Project Muscular Dystrophy Help Fund Next Step in Cutting-Edge Treatment
There is still a very strong appetite for individual stocks with momentum.
The indices are hitting highs as the market shrugs off yesterday's rotation.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
Look for an increase to the low $60s followed by the $75 area longer term.
We have shifted from a market that was mainly index driven by the FAANG names to one where stock picking is more important.
-- Capped call transactions raise the effective conversion price of the notes to $104.88, subject to future adjustments --
-- Chief executive officer purchases approximately $2 million of shares of Sarepta's common stock --
Tightening stops, closely watching momentum stocks and considering index shorts as I get more defensive.
The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.
-- Sarepta to immediately initiate a Phase 1/2a clinical trial in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51 --
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.